What Is NNMT? The Enzyme 5-Amino-1MQ Targets

The best-known NNMT inhibitor on the research market, 5-Amino-1MQ, sells for $33.60 as a capsule, yet very few buyers can say what the enzyme it targets actually does. NNMT stands for nicotinamide N-methyltransferase. The name describes its job: it adds a methyl group to nicotinamide, a form of vitamin B3. In mouse studies of diet-induced obesity, blocking it with 5-Amino-1MQ reduced fat mass and body weight.

This page explains the enzyme, its link to NAD+, and what the inhibitor idea does and does not prove. I keep the biochemistry short, because the useful part for buyers is understanding where the evidence stops.

NNMT in plain terms

NNMT is an enzyme that tags nicotinamide with a methyl group, turning it into a form the body then clears. It is one of many enzymes that decide how much of a nutrient is used and how much is discarded.

Nicotinamide is not a minor molecule. It is a form of vitamin B3 and a building block the body recycles into NAD+. When NNMT methylates nicotinamide, that molecule is taken out of the recycling loop.

The enzyme is found in several tissues, not only in fat, and research groups study it in liver and fat models among others. That point comes back later, because a drug aimed at fat cells would also reach those other tissues.

The link between NNMT and NAD+

NNMT links to NAD+ because both draw on the same supply of nicotinamide. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme in every cell and is central to energy metabolism.

The idea researchers explore is simple: if NNMT consumes less nicotinamide, more may stay available for NAD+ pathways, and fat cells may handle energy differently. That idea is a hypothesis drawn from lab and animal work, not a proven effect in people.

This link also explains why vendors place 5-Amino-1MQ beside NAD+ products. Real Peptides lists an NAD+ multi-dose vial at $60.00 for research use, and the metabolic compounds comparison sets the two next to each other.

How an NNMT inhibitor is supposed to work

An NNMT inhibitor is supposed to slow the enzyme down so that less nicotinamide is methylated. In practice, the evidence for what follows comes from animal models.

1. The inhibitor binds the enzyme and reduces its activity.
2. Less nicotinamide is methylated and removed.
3. Researchers propose that this shifts energy handling in fat tissue.
4. In diet-induced obese mice, fat mass and body weight were reported to fall.

Steps one and two describe a mechanism. Step three is a proposal. Step four is the actual measured result, and it was measured in mice. The benefits page goes through that outcome in more detail.

5-Amino-1MQ as the best-known example

5-Amino-1MQ is the NNMT inhibitor most buyers encounter, and it is a small molecule rather than a peptide. Research vendors still list it as "5-Amino-1MQ Peptide" because they sell it alongside peptides.

It was not among the compounds reviewed by FDA's compounding advisory committee in July 2026, and it was not named in FDA's 24 August 2026 warning letters to five online peptide vendors. Neither fact says anything about safety; they only mean regulators have not acted on it specifically. Absence from a warning letter is not a clean bill of health.

Limits of the NNMT story

The NNMT story has clear limits: it is a mechanism with animal results, and nothing more has been established. Several gaps remain open.

• No published controlled human trials of any NNMT inhibitor sold by research vendors.
• Long-term effects of blocking an enzyme found in several tissues are unknown.
• No human dose exists, and mouse amounts cannot be translated.
• Interactions with medicines and existing conditions have not been studied.

Those gaps are why the side effects page is mostly a list of unknowns. It is also why the mechanism, however tidy it looks on paper, should not be read as a promise.

We find the NNMT inhibitor concept genuinely interesting as research. As a product, 5-Amino-1MQ is an unapproved chemical sold for laboratory use, and anyone thinking about their own metabolism should talk to their doctor about approved options.